

Complete listing of claims:

1. (previously presented) A method for identifying agents that are inhibitors of tau-beta amyloid complex formation comprising:
 - (a) contacting said tau protein derived polypeptide and said aggregated beta-amyloid peptide in the presence and absence of a test agent; and (b) determining the amount of tau-beta amyloid complex formed in the presence and absence of the test agent; and
 - (c) comparing the amount of tau-beta amyloid complex formed in the presence of the test agent with the amount of tau-beta amyloid complex formed in the absence of the test agent wherein a test agent which decreases the amount of tau-beta amyloid complex formed is an inhibitor.
2. (previously presented) The method of claim 1 wherein said tau derived polypeptide comprises residues 244-390 of SEQ ID NO:2.
3. (previously presented) The method of claim 1 wherein said tau derived polypeptide comprises residues 186-332 of SEQ ID NO:4.
4. (previously presented) The method of claim 1 wherein said tau derived polypeptide comprises residues 186-279 of SEQ ID NO:6.
5. (previously presented) The method of claim 1 wherein said aggregated beta-amyloid peptide comprises residues 1-39 of SEQ ID NO:7.
6. (previously presented) The method of claim 1 wherein said aggregated beta-amyloid peptide comprises residues 1-40 of SEQ ID NO:7.
7. (previously presented) The method of claim 1 wherein said aggregated beta-amyloid peptide comprises residues 1-41 of SEQ ID NO:7.
8. (previously presented) The method of claim 1 wherein said aggregated beta-amyloid peptide comprises residues 1-42 of SEQ ID NO:7.
9. (cancelled)
10. (cancelled)
11. (original) The method of claim 1 wherein the amount of tau-beta amyloid complex is determined by polyacrylamide gel electrophoresis.

12. (original) The method of claim 1 wherein the amount of tau-beta amyloid complex is determined by turbidity measurement.
13. (original) The method of claim I wherein the amount of tau-beta amyloid complex is determined by gel shift assay.
14. (original) The method of claim I wherein the amount of tau-beta amyloid complex is determined by antibody binding.
15. (original) The method of claim 1 wherein the amount of tau-beta amyloid complex is determined by ELISA.
16. (previously presented) The method of claim 1 wherein the amount of tau-beta amyloid complex is determined by Western blotting.
17. (original) The method of claim I wherein the amount of tau-beta amyloid complex is determined by fluorescence polarization.
18. (cancelled)
19. (original) The method of claim 1 wherein the tau protein derived polypeptide is labeled.
20. (original) The method of claim I wherein the tau protein derived polypeptide comprises a tag.